

Attorney Docket No.: RTS-0250
Inventors: Monia et al.
Serial No.: 09/954,556
Filing Date: September 14, 2001
Page 2

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

B1
Claim 1 (currently amended): A compound 8 to 50 nucleobases in length targeted to a 5'-untranslated region, nucleobases 308 through 994 or nucleobases 1317 through 2720 of a coding region, a stop codon region, or a 3'-untranslated region of a nucleic acid molecule encoding human fibroblast growth factor receptor 2, wherein said compound specifically hybridizes with said nucleic acid molecule encoding human fibroblast growth factor receptor 2 (SEQ ID NO: 3) and inhibits the expression of human fibroblast growth factor receptor 2.

Claim 2 (original): The compound of claim 1 which is an antisense oligonucleotide.

Claim 3 (canceled)

Attorney Docket No.: RTS-0250
Inventors: Monia et al.
Serial No.: 09/954,556
Filing Date: September 14, 2001
Page 3

Claim 4 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

Claim 5 (original): The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

B |
Claim 6 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

Claim 7 (original): The compound of claim 6 wherein the modified sugar moiety is a 2'-o-methoxyethyl sugar moiety.

Claim 8 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

Claim 9 (original): The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

Attorney Docket No.: RTS-0250
Inventors: Monia et al.
Serial No.: 09/954,556
Filing Date: September 14, 2001
Page 4

Claim 10 (original): The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

Claim 11 (canceled)

Claim 12 (original): A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

B
Claim 13 (original): The composition of claim 12 further comprising a colloidal dispersion system.

Claim 14 (original): The composition of claim 12 wherein the compound is an antisense oligonucleotide.

Claim 15 (original): A method of inhibiting the expression of fibroblast growth factor receptor 2 in cells or tissues comprising contacting said cells or tissues with the compound of claim 1 so that expression of fibroblast growth factor receptor 2 is inhibited.

Claims 16-20 (canceled)